One Nucleus Appoints Director

One Nucleus, the not-for-profit membership company for international life science and healthcare companies, is delighted to announce the appointment of Dr Alan Palmer as a Director. Alan is co-founder and currently Chief Scientific Officer for MS Therapeutics Ltd and has 30 years’ experience in the biotechnology sector in roles spanning academia, research and industry.

Alan has close ties with the London life science and healthcare community and was a strong supporter of the London Biotechnology Network (LBN), now part of One Nucleus.

Commenting on his appointment Dr Palmer said: “I have worked with both Harriet (Fear) and Tony (Jones) for many years and am very excited about the merger of ERBI and LBN to form One Nucleus.

“These are challenging times and One Nucleus is extremely well placed to support the biotechnology sector. I am delighted to have been asked to join the Board and look forward to bringing my experience to the table, to support the team and One Nucleus members into the future.”

Harriet Fear, CEO of One Nucleus commented: “Alan is a great addition to the team. He has a deep understanding of the needs of One Nucleus members, and this coupled with his academic and pharma background makes him an ideal Director for One Nucleus.”